DB
Therapeutic Areas
Atriva Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zapnometinib (ATR-002) | Influenza | Phase 2 |
Leadership Team at Atriva Therapeutics
DR
Dr. Rainer Lichtenberger
Chief Executive Officer
PD
Prof. Dr. Oliver Planz
Co-founder & Chief Scientific Officer